Genetics prevail

Why EcoR1 joined $75M series A for neurodegenerative disease play Prevail

Prevail Therapeutics Inc.’s focus on genetic subpopulations of patients with neurodegenerative diseases led EcoR1 Capital to join the newco’s tranched $75 million series A round.

The round’s investors included OrbiMed Advisors, Pontifax Fund, RA Capital Management, EcoR1, Omega

Read the full 388 word article

User Sign In